Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02460978 · ClinicalTrials.gov registry record · Phase 3
Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 815
- Enrollment target
NCT02460978: Completed Phase 3 study, sponsored by AstraZeneca.
NCT02460978 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 815 participants, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02460978, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 815 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if adding dapagliflozin to insulin is a safe and effective therapy to improve glycemic control in patients with type 1 diabetes.
Primary Outcome
To compare the change from baseline in HbA1c between dapagliflozin 5 mg or 10 mg plus adjustable insulin versus placebo plus adjustable insulin after 24 weeks of double-blinded treatment
Interventions
- DRUG Dapagliflozin
- OTHER Placebo for dapagliflozin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 815 participants |
| Start Date | 2015-07-08 |
| Est. Completion | 2018-04-18 |
| Phase | Phase 3 |
What the finished NCT02460978 record still lists
NCT02460978 is an interventional study that assigns participants to a tested intervention. The registered 815 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target.
The record links to 0 conditions, and to 2 interventions - of which Dapagliflozin is the first listed.
NCT02460978 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02460978 about?
NCT02460978 is a clinical study titled "Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes". The purpose of this study is to determine if adding dapagliflozin to insulin is a safe and effective therapy to improve glycemic control in patients with type 1 diabetes.
What is the current status of trial NCT02460978?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 815 participants. The study started on 2015-07-08. Estimated completion is 2018-04-18.
What interventions are being tested in trial NCT02460978?
The interventions under investigation include: Dapagliflozin (DRUG), Placebo for dapagliflozin (OTHER).
Who is sponsoring clinical trial NCT02460978?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02460978's enrollment target sits among peer trials
815 406th of 2000 higher than 1,594 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07218029 · 815 participants · Phase 3
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)
- NCT04846959 · 818 participants
Study to Evaluate Pregnancy Outcomes in Risankizumab Exposed Pregnancies Relative to Those Non-risankizumab Exposed Pregnancies in Women With FDA Approved Indications
- NCT04028687 · 820 participants
MDR - PMCF Study for Taperloc Complete Stems
- NCT04613440 · 820 participants · NA
FaCT Trial (Facilitated Cascade Testing Trial)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI